Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer Meeting Abstract
| Authors: | Rugo, H. S.; Bardia, A.; Marine, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tredan, O.; Ciruelos, E.; Dalenc, F.; Pardo, P. G.; Jhaveri, K. L.; Delaney, R.; Fu, O.; Lin, L. J.; Verret, W.; Tolaney, S. M. |
| Abstract Title: | Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-10 |
| Language: | English |
| ACCESSION: | WOS:000891791500011 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.17_suppl.LBA1001 |
| Notes: | Meeting Abstract: LBA1001 -- Source: Wos |
